Drugs Made In America Acquisition Corp
DMAA
24 hedge funds and large institutions have $171M invested in Drugs Made In America Acquisition Corp in 2025 Q1 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
58.79% more ownership
Funds ownership: 0% → 58.79% (+59%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$23.2M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$22.1M |
| 3 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$20.7M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$19M |
| 5 |
GCL
Glazer Capital LLC
New York
|
+$18.2M |
Top Sellers
DMAA Hedge Fund Activity: Q1 2025 in Review
24 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp (DMAA) for Q1 2025, worth a combined $171M.
Buyers outnumbered sellers: 24 funds opened new DMAA positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Karpus Investment Management, opening a new position worth an estimated $23.2M.
- 24 institutional investors held Drugs Made In America Acquisition Corp (DMAA) as of Q1 2025, up from 0 in Q4 2024.
- Funds reported $171M of Drugs Made In America Acquisition Corp stock for Q1 2025.
- 24 funds opened new Drugs Made In America Acquisition Corp positions in Q1 2025 and 0 closed out, a net change of +24 holders.
- The largest Drugs Made In America Acquisition Corp buyer in Q1 2025 was Karpus Investment Management, an estimated $23.2M added.
Based on aggregated 13F filings for Q1 2025.